EchoStar Communications

(DISH) - Get Report

rose more than 19% on news that it is in the final stages of negotiating a $29.5 billion buyout deal with telecom giant

AT&T

(T) - Get Report

.

EchoStar's Dish Network could help AT&T expand outside its largely Southwestern markets and give it the video expertise and programming agreements to operate on a national level, say analysts. The final price for the satellite-TV operator, still under negotiation, is likely to range from $64 to $68 a share, according to

a story on

TheStreet.com

. EchoStar was up $7.66, or 19.2%, to $47.49. Meanwhile AT&T was down $1.80, or 4.6%, to $37.75.

Micrel

(MCRL)

soared nearly 12% after the company signed a multimillion-dollar, long-term contract with a solar company to supply commercial solar cells. Micrel did not disclose details of the contract, including the identity of the partner, but it did say it will fabricate the concentrated solar cells at its San Jose, Calif., site. Micrel was up 98 cents to $9.20.

Celgene

(CELG) - Get Report

said it would buy fellow blood-cancer drug company

Pharmion

( PHRM) in a $2.9 billion

cash-and-stock deal. Celgene will pay $72 a share for Pharmion -- $25 in cash and $47 in Celgene stock. The price is a 46% premium to Pharmion's Friday closing price.

Pharmion shares rose $15.84, or 32.1%, to $65.12, and Celgene fell 90 cents, or 1.4%, to $64.00. Both stocks are components of the Nasdaq biotechnology index, which was down 12.55, or 1.5%, to 835.66.

Amarin

(AMRN) - Get Report

gave an update Monday, saying it met with the FDA following the completion of a comprehensive data review from its phase III studies of Miraxion for Huntington's disease, and the agency indicated another phase III trial with robust results may be sufficient to support a new-drug application.

The company said it's in discussions with the Huntington Study Group to determine the design of the phase III trial, and is considering whether it will conduct this study itself or seek a partner to advance Miraxion in Huntington's disease. Shares garnered 13 cents, or 45.2%, to 43 cents.

Meanwhile,

The Wall Street Journal

highlighted that mortgage investors

Freddie Mac

( FRE) and

Fannie Mae

( FNM) are beginning to show symptoms of the credit-crunch plague as the housing market continues to sink, and pointed out that they have some exposure to subprime mortgages.

That makes investors nervous, said the

Journal

, especially ahead of Freddie's scheduled earnings report tomorrow. Fannie, for its part, today was hit with a Friedman Billings downgrade to market perform from outperform, which comes on the heels of last week's share-hammering

Fortune

report that it could be using

accounting tricks in order to brightly skew its credit-loss ratio. Freddie and Fannie shares were off 7.9% and 7.2%, respectively, in heavier-than-usual trading.

Goldman also chopped $9 off

E*Trade's

(ETFC) - Get Report

price target to $6 after last week's

downgrade-catalyzed beatdown, which followed word of

significant fourth-quarter writedowns at the online broker. Last week, shares partially rebounded from the initial Monday plummet; today they pulled back 11.6% at $4.81.

Indianapolis footwear retailer

Finish Line

(FINL)

jumped 4% to $3.51 after

UBS

(UBS) - Get Report

petitioned a Tennessee court Friday to relieve it from its obligation to finance Finish Line's $1.5 billion merger buyout of fellow shoe seller

Genesco

(GCO) - Get Report

.

On the losing side of the UBS move, Genesco plummeted 21% to $31.08.

Golar LNG

(GLNG) - Get Report

, a Hamilton, Bermuda-based natural gas shipping company, lost 11% to $21.51 after the company announced it issued 3.2 million new shares to finance expansion of its carrier fleet.